Abstract
Efficacy of PDT with new chlorin e6 photosensitizer (BLC 1010) has been tested in 72 cancer patients. 44 patients (61 %) achieved a complete response and 39 % of the patients a partial response (28 patients, including 15 patients treated for palliation).
Rapid elimination of BLC 1010 from the organism solves the problem of skin phototoxicity encountered in PDT up to now. This property together with its high tumor to normal ratio makes it a promising photosensitizer for PDT. Further advantage is that portable diode lasers with proper wavelength are available.
© 2001 OSA/SPIE
PDF ArticleMore Like This
Valery A. Privalov, Elena V. Kochneva, and Alexander V. Lappa
TuD4 European Conference on Biomedical Optics (ECBO) 2005
Aleksander Sieron, Mariusz Adamek, Tomasz Biniszkiewicz, Wojciech Cebula, Grzegorz Cieslar, Aleksandra Kawczyk - Krupka, Grzegorz Niepsuj, Michał Szygula, Boguslaw Wojciechowski, and Witold Zieleznik
4433_120 European Conference on Biomedical Optics (ECBO) 2001
E. Alexandratou, M. Kyriazi, T. Trebst, S. Gräfe, and D. Yova
6632_19 European Conference on Biomedical Optics (ECBO) 2007